Key Takeaways
- Record revenue, margin normalization on track: Q2 FY27 delivered the highest-ever quarterly revenue, lifting H1 operational EBITDA margin to 35.1%, squarely within the mid-30s full-year guidance.
- Order book keeps growing: Order inflow of ₹481.8 crores outpaced revenue execution of ₹345.1 crores, so the backlog expanded even as execution accelerated.
- C-UAS orders are the big, late catalyst: FTP tenders are expected in weeks, with a hard procurement deadline of March 31, 2027; the bulk of new orders hinges on this process concluding on time.
- Working capital stretched, not stressed: The cash cycle hit 379 days as receivables piled up from the Q2 execution ramp, but the debt is recent, government-backed, and funded entirely from internal resources.
- What to watch next quarter: Whether FTP RFPs actually drop, the pace of simulator order conversion (~₹400 Cr expected), and any export order closure from the Middle East or CIS, where near-final talks have been delayed by regional conflict.
Revenue & Execution
- Q2 surge, as promised: Revenue was heavily weighted to Q2 and Q3, consistent with prior communication, and reflected the order book built since last year. Some spillover from Q1 also contributed.
- Execution engine upgraded: New processes and systems now provide visibility into bottlenecks, letting the company execute smoothly even if the order book doubled. Typical execution timelines have compressed to 12–18 months from order receipt, with only minor spillover possible beyond that.
- H1 done, H2 mapped: ₹485 Cr executed in H1; the remaining ₹715–815 Cr of the full-year target is spread over Q3 and Q4, with management seeing no execution challenge even if Q2 is very heavy.
- FY27 revenue comfort: Management is comfortable achieving ₹1,200–1,300 Cr and stated it "should be able to achieve a little more than that number."
- The ₹4,000 Cr two-year target: That number was based on government processing orders and the company receiving them in hand; some placement delays are occurring, but once orders land, execution confidence is very high.
Ashok Atluri: "What we are very sure about is the ability to execute the order that we have already got. So, that ₹4000 Crore that we made for two financial years was based on the government processing the orders and we getting the orders in hand. So, we expect those things to happen, but we do not know when they will happen."
Margins & Costs
- Operating leverage delivered: Operational EBITDA margin normalized to 38.2% in Q2 (vs 37.3% YoY and 27.3% QoQ), confirming the prior commitment that margins would recover toward the guided 35% as revenue scaled.
- Cost base stayed efficient: Employee and other expenses together fell to 24.4% of revenue from 26.3% a year ago, even though absolute spending rose on performance incentives and R&D headcount.
- Warranty mix effect: Other expenses rose partly because a higher mix of ADS products drove ₹9.3 crores more in warranty provisioning YoY; consultancy and professional fees for R&D pipeline products also increased.
- 35% is the steady state, not a downgrade: FY26's 48% EBITDA margin was an outlier driven by a simulator-heavy mix; the long-term guided ~35% reflects normal mix variation between ADS and simulators.
Order Book & Working Capital
- Inflow exceeded outflow: Q2 order inflow of ₹481.8 Cr surpassed revenue of ₹345.1 Cr, so the order book grew even as execution hit a record.
- Cash cycle stretched by success: Working capital days rose to 379, driven by two factors: debtor days increased because receivables are recent and concentrated in the Q2 ramp, and advances to suppliers grew as procurement for the remainder-of-year delivery schedule accelerated. Inventory days actually fell.
- Low collection risk: Receivables are largely from government and defense contracts; the entire working capital build has been funded from internal resources.
- Order book execution question: When asked if the ₹995 Cr order book could be fully consumed by March, management redirected to the ₹1,200–1,300 Cr full-year topline answer without directly addressing whether the entire backlog would clear within FY27.
C-UAS: The Big Pipeline, The Big Wait
- Two procurement routes, two clocks: FTP (Fast Track Procurement) approvals have happened and RFPs are expected in weeks; the deadline to finish procurement is March 31, 2027. The capital acquisition route is expected to take two to three years to play out.
- Earliest major orders in Q4 FY27: That timeline is contingent on the FTP process concluding by its March 31 deadline. If it slips, orders spill into Q1 or, worst case, Q2 FY28, though historically it has never gone beyond Q2.
- Zen's positioning: The company expects a fair share given proven systems, including deployment in Operation Sindoor, but cannot quantify until tenders are floated and specifications known. The C-UAS command and control systems are being made AI-native, with the product the armed forces see three to six months from now being completely different from today's.
- Product philosophy: The company is building a counter-drone system "for war, not for winning a particular tender," a stance management believes will differentiate it from resellers of foreign goods when the government evaluates Indian IP.
Ashok Atluri: "Even if they were to buy something today, tomorrow they would want it to change and that is where, is the Company buying from an Indian Company with the Indian IP or are they buying from some collaborator, who is reselling the foreign goods, so that will be the biggest challenge there."
Exports & New Markets
- Near-term export hopes: Some orders are expected in the next few months from the Middle East, CIS countries, and Southeast Asia, though the Iran-Israel war has delayed near-final negotiations.
- Middle East: interest without urgency: Management is in talks with friendly governments but noted "strangely no orders have come through" and "there is nothing in advanced stage with the Middle East governments at this point in time." The economic mismatch of cheap attack drones vs expensive interceptors has not yet translated into procurement action.
- US and Europe: long-term plays: For the US, the company is working on compliance and collaborating with primes, expecting something "probably next year." For Europe, talks with large players aim to meet local procurement requirements (65% local under SAFE) for both C-UAS and simulators, with positive developments expected by early next year.
- The black swan upside: Europe and America are seen as "really, really good and interesting markets" in the long term; if the company gets a crack there, management calls it a "very, very pleasant positive black swan."
Ashok Atluri: "We are in talks with some of the Middle East governments ... but it is strange that there is not a sense of that urgency with them ... a very bad arithmetic of, they send a \$20,000 Shahed and these people are spending \$4 million to block it."
Products, R&D & Acquisitions
- R&D: opportunistic and IP-focused: R&D spend for FY27 is expected in a similar range as FY26 (~12% of topline), though no internal benchmark is set. Investment goes into robotics, AI, anti-drone systems, and next-gen solutions in existing product areas. Every acquisition is treated as an IP purchase.
- Cogknit acquisition: Brings AI and command-and-control technology, including situational awareness for tanks, fitting the strategy of acquiring Pareto technologies that deliver 80% of the outcome in war.
- Naval simulator suite: The ARI and Anawave acquisitions together provide a complete marine simulator suite now transformed into naval simulators (submarine, fast attack craft), branded as "naval CTCs." Discussions are underway with various navies globally, and management is "very positive" about growth over the next three to four years, with a pipeline growing "really, really big."
- Hyper Strike: The product is undergoing internal trials. First orders are expected in FY28, with the majority in FY29, ramping slowly from ~600 units per month. Management expects "definitely some significant contribution to happen by the next year." The capacity being built is close to 15,000 units per month, with an eventual annual capacity of 180,000 units.
- Patent grants: The company has stopped issuing press releases for individual patents due to frequency (~one every 10 days) and plans consolidated announcements going forward.
Ashok Atluri: "We are very opportunistic when it comes to R&D expenses, if we see there is any kind of development, which we think is a huge opportunity and which the country needs we go all in and we do not mind investing our own money and that has been the USP of Zen till now..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EBITDA margin | Mid-30s operational EBITDA margin | FY27 |
| FY27 revenue | Comfortable achieving ₹1,200–1,300 Cr, "should be able to achieve a little more" | FY27 |
| Simulator orders | ~₹400 plus crores of simulator orders expected to materialize | Earlier than C-UAS FTP orders |
| C-UAS FTP orders | Earliest major orders contingent on FTP process concluding | Q4 FY27, spill to Q1/Q2 FY28 if delayed |
| FTP RFP publication | RFPs expected to be floated | In the next few weeks, if not months |
| Hyper Strike first orders | First orders expected, ramp from ~600 units/month | FY28, majority in FY29 |
| Capex | ~₹150 Cr budgeted | Each of FY27 and FY28 |
| Export orders (near-term) | Some orders expected from Middle East, CIS, Southeast Asia | Next few months |
| US market entry | Working on compliance, collaborating with primes | "Probably next year" |
| Europe market entry | Positive developments expected on local procurement partnerships | By next year at least in the beginning of the next year |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹345.1 cr, highest ever quarterly revenue, +98.8% YoY and +143.7% QoQ |
| Operational EBITDA | ₹132 cr, margin of 38.2% vs 37.3% in Q2 FY26 and 27.3% in Q1 FY27 |
| Operational EBITDA margin | 38.2%, up 90 bps YoY; operating leverage and product mix drove expansion |
| Profit after tax | ₹89.5 cr, +50.7% YoY over ₹59.4 cr in Q2 FY26 |
| H1 FY27 operational EBITDA margin | 35.1%, in line with mid-30s full-year guidance |
| H1 FY27 revenue | ₹486.8 cr, +46.7% YoY over ₹331.8 cr in H1 FY26 |
| H1 FY27 profit after tax | ₹124 cr, vs ₹107.2 cr in H1 FY26 |
| Full-year FY27 revenue guidance | ₹1,200–1,300 cr, management comfortable and expects to achieve a little more |
| Long-term EBITDA margin guidance | ~35%, product mix between ADS and simulators drives quarterly variation |
| Order book | ₹1,375.7 cr as of Sep 30, 2026, comprising ₹995 cr equipment and ₹380.7 cr AMC |
| Order inflow during Q2 | ₹481.8 cr, exceeding quarterly revenue execution of ₹345.1 cr |
| Order book growth | ₹1,239 cr at start of Q2 to ₹1,375.7 cr at quarter end |
| Working capital cycle | 379 days as of Sep 30, 2026, up from 255 days at end of Q1, driven by receivables and supplier advances |
| Cash and bank balances | ₹968 cr, company remains debt free |
| Net operating cash flow (H1 FY27) | Negative, a function of working capital build from back-ended revenue and inventory deployment |
| R&D expense (FY26) | 12% of topline, expected to remain in similar range for FY27 |
| FY27 budgeted capex | ₹150 cr, with a similar amount budgeted for FY28 |
| Patents applied for | More than 235, with grants at approximately one every 10 days |
| Hyper Strike capacity | 15,000 units per month on three shifts, 180,000 units per annum at an assumed average price of ~\$10,000 per unit |
| C-UAS addressable market share | 70–80% of armed forces C-UAS tenders addressable by Zen |
| Simulator orders expected | ₹400+ cr of simulator orders anticipated, though timing remains uncertain |